Laura Stoppel - 03 Jun 2026 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Reporting relationship: Director
Issuer ticker: ABOS
Reported as of: 03 Jun 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2026, 16:27:28 UTC
Prior SEC filing: 26 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Derek Meisner, Attorney-in-Fact

Key filing fact

Laura Stoppel filed Form 4 for Acumen Pharmaceuticals, Inc. (ABOS) on 05 Jun 2026.

Key facts

This page summarizes Laura Stoppel's Form 4 filing for Acumen Pharmaceuticals, Inc. (ABOS).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 05 Jun 2026, 16:27.

Change

Previous filing in this sequence was filed on 26 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001865119 Primary reporting owner

Stoppel Laura

Relationship: Director
Address: C/O RA CAPITAL MANAGEMENT, 200 BERKELEY STREET, 18TH FLOOR, BOSTON
Signature: /s/ Derek Meisner, Attorney-in-Fact
Signature date: 05 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ABOS transaction

Common Stock

Award

Transaction value
Shares: +35,500
Change %: +277%
Price: $0.000000^*
Shares after: 48,300
Date: 03 Jun 2026
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ABOS transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +53,250
Change %
Price: $0.000000^*
Shares after: 53,250
Date: 03 Jun 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 53,250
Exercise price: $2.29
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

Represents a restricted stock unit ("RSU") award. Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. The RSUs will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.

Footnote F2

Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the option and RSUs for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund II, L.P. (the "Nexus Fund II") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option or settlement of the RSUs, as applicable, which will offset advisory fees owed by the Fund, the Nexus Fund II and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the option and RSUs and underlying common stock.

Footnote F3

The shares subject to the option will vest in full on the earlier of the first anniversary of the date of grant or the 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date.